Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

Open access
The ASCEND Study Collaborative Group · 2018 · New England Journal of Medicine

Abstract

BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).

Overview

CoChat Summary

TL;DR

In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.

Key findings

  • Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
  • Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
  • No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
  • Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.

Methods

  • Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
  • Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
  • Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.

Limitations

  • Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
  • Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
  • Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1804988

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations

37 more claims · 6 with their cited sources checked

Create a free account to see all 72 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

17 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 23 references

Cited by

See all 1,200

Metadata

Authors
The ASCEND Study Collaborative Group
Affiliations
MRC Population Health Research Unit (GB)
Corresponding author
The ASCEND Study Collaborative Group
Venue
New England Journal of Medicine
Published
2018-10-18
Volume
379
Issue
16
Pages
1529-1539
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2899755710
Cited by
1,200
References
23
Citations by year
2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
FWCI
116.42
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders
  • Mylan EPD
  • Solvay Pharmaceuticals
  • Bayer Schering
  • British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
MeSH terms
Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. https://app.cochat.ai/papers/10.1056/nejmoa1804988
The paper
The ASCEND Study Collaborative Group. (2018). Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1804988

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.